1-3 of 3
David Barrett, MD, PhD
Close
Sort by
Journal Articles

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Marco Ruella, MD, David Barrett, MD PhD, Saad S. Kenderian, MD, Olga Shestova, PhD, Ted J. Hofmann, PhD, John Scholler, Simon F. Lacey, PhD BSc, Jan J Melenhorst, PhD, Farzana Nazimuddin, MS, Michael Kalos, PhD, David L. Porter, MD, Carl H. June, MD, Stephan A. Grupp, MD PhD, Saar I. Gill, MD PhD
Journal: Blood
Blood (2014) 124 (21): 966.
https://doi.org/10.1182/blood.V124.21.966.966
Published: 2014
Journal Articles

Removal of Normal Competition Increases Proliferation of Pre-Leukemic Cells in a Mouse Model of Pre-B Acute Lymphoblastic Leukemia.

Gregor SD Reid, PhD, David Barrett, MD, PhD, Alix Eden Seif, MD, MPH, Valerie I. Brown, MD, PhD, Stephan A. Grupp, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1430.
https://doi.org/10.1182/blood.V114.22.1430.1430
Published: 2009
Journal Articles

Inhibiting PIM-1 Is Effective in Vitro and in Vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target.

Valerie I. Brown, MD, PhD, Cecilia Sheen, Jessica Hulitt, Theresa Ryan, Laura DiNardo, David Barrett, MD, PhD, David T. Teachey, MD, David J. Bearss, PhD, Gregory I. Berk, MD, Stephan A. Grupp, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1922.
https://doi.org/10.1182/blood.V112.11.1922.1922
Published: 2008